March 28 (Reuters) - The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' MIST.O nasal spray to treat a type of heart condition, the company said on Friday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.